IRWD vs. INVA, OPK, MNKD, CYRX, DVAX, IGMS, LGND, KURA, LXRX, and VSTM
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Innoviva (INVA), OPKO Health (OPK), MannKind (MNKD), Cryoport (CYRX), Dynavax Technologies (DVAX), IGM Biosciences (IGMS), Ligand Pharmaceuticals (LGND), Kura Oncology (KURA), Lexicon Pharmaceuticals (LXRX), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.
In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than Innoviva. MarketBeat recorded 10 mentions for Ironwood Pharmaceuticals and 3 mentions for Innoviva. Ironwood Pharmaceuticals' average media sentiment score of 1.51 beat Innoviva's score of 0.10 indicating that Innoviva is being referred to more favorably in the media.
Innoviva has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva has a net margin of 58.21% compared to Innoviva's net margin of -254.41%. Ironwood Pharmaceuticals' return on equity of 28.94% beat Innoviva's return on equity.
Innoviva has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Ironwood Pharmaceuticals has a consensus target price of $18.40, suggesting a potential upside of 183.95%. Given Innoviva's higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Innoviva.
99.1% of Innoviva shares are held by institutional investors. 1.4% of Innoviva shares are held by insiders. Comparatively, 13.1% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Ironwood Pharmaceuticals received 209 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 61.09% of users gave Ironwood Pharmaceuticals an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Summary
Innoviva and Ironwood Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
